**Name of Journal: *World Journal of Gastroenterology***

**Manuscript NO: 38950**

**Manuscript Type: META-ANALYSIS**

**Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis**

Jiang XW *et al*. HBV reactivation during anti-HCV therapy

Xian-Wan Jiang, Jian-Zhong Ye, Ya-Ting Li, Lan-Juan Li

**Xian-Wan Jiang, Jian-Zhong Ye, Ya-Ting Li, Lan-Juan Li,** State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China

**Xian-Wan Jiang, Jian-Zhong Ye, Ya-Ting Li, Lan-Juan Li,** Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou 310003, Zhejiang Province, China

**ORCID number:** Xian-Wan Jiang (0000-0003-0982-7306); Jian-Zhong Ye (0000-0001-8174-2580); Ya-Ting Li (0000-0002-0761-4967); Lan-Juan Li (0000-0001-6945-0593).

**Author contributions:** Jiang XW, Ye JZ, Li YT and Li LJ contributed the data extraction and statistical analysis; Jiang XW wrote the manuscript; Ye JZ, Li YT and Li LJ reviewed the manuscript; all authors have approved the final version of the manuscript.

**Supported by** the National Natural Science Foundation of China, No. 81330011; and the Science Fund for Creative Research Groups of the National Natural Science Foundation of China, No. 81721091.

**Conflict-of-interest statement:** There is no conflict of interest in this study.

**PRISMA 2009 Checklist statement:** The PRISMA checklist has been adopted.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript Source:** Unsolicited Manuscript

**Correspondence to: Lan-Juan Li, MD, PhD, Professor,** State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. ljli@zju.edu.cn

**Telephone:** +86-571-87236759

**Fax:** +86-571-87236459

**Received:** March 28, 2018

**Peer-review started:** March 28, 2018

**First decision:** May 9, 2018

**Revised:** June 2, 2018

**Accepted:** June 22, 2018

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To assess the incidence of hepatitis B virus (HBV) reactivation in patients receiving direct-acting antiviral agent (DAA)-based therapy or interferon (IFN)-based therapy for hepatitis C and the effectiveness of preemptive anti-HBV therapy for preventing HBV reactivation.

***METHODS***

The PubMed, MEDLINE and EMBASE databases were searched, and 39 studies that reported HBV reactivation in HBV/hepatitis C virus coinfected patients receiving DAA-based therapy or IFN-based therapy were included. The primary outcome was the rate of HBV reactivation. The secondary outcomes included HBV reactivation-related hepatitis and the effectiveness of preemptive anti-HBV treatment with nucleos(t)ide analogues. The pooled effects were assessed using a random effects model.

***RESULTS***

The rate of HBV reactivation was 21.1% in hepatitis B surface antigen (HBsAg)-positive patients receiving DAA-based therapy and 11.9% in those receiving IFN-based therapy. The incidence of hepatitis was lower in HBsAg-positive patients with undetectable HBV DNA compared to patients with detectable HBV DNA receiving DAA therapy (RR = 0.20, 95%CI: 0.06-0.64, *P* = 0.007). The pooled HBV reactivation rate in patients with previous HBV infection was 0.6% for those receiving DAA-based therapy and 0% for those receiving IFN-based therapy, and none of the patients experienced a hepatitis flare related to HBV reactivation. Preemptive anti-HBV treatment significantly reduced the potential risk of HBV reactivation in HBsAg-positive patients undergoing DAA-based therapy (RR = 0.31, 95%CI: 0.1-0.96, *P* = 0.042).

***CONCLUSION***

The rate of HBV reactivation and hepatitis flare occurrence is higher in HBsAg-positive patients receiving DAA-based therapy than in those receiving IFN-based therapy, but these events occur less frequently in patients with previous HBV infection. Preemptive anti-HBV treatment is effective in preventing HBV reactivation.

**Key words:** Hepatitis C; Coinfection; Hepatitis B virus reactivation; Direct-acting antiviral agents; Meta-analysis

© **The Author(s) 2018**. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** We assessed the potential risk of hepatitis B virus (HBV) reactivation in patients receiving direct-acting antiviral agent (DAA)-based therapy or interferon-based therapy for hepatitis C. Preemptive anti-HBV treatment proved to be effective in preventing HBV reactivation during DAA therapy. These findings support the use of entecavir or tenofovir in hepatitis B surface antigen-positive patients prior to the initiation of DAA therapy.

Jiang XW, Ye JZ, Li YT, Li LJ. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. *World J Gastroenterol* 2018; In press

**INTRODUCTION**

Hepatitis B virus/hepatitis C virus (HBV/HCV) dual infection is common in regions with a high HBV prevalence, as HBV and HCV share a similar mode of transmission[1]. The global prevalence of HBV/HCV dual infection is approximately 5%-10% in patients with chronic HCV infection, and the prevalence is reported to be 8.4% in China and 12%-14% in East Asia[2]. HBV/HCV-coinfected patients tend to have more severe liver fibrosis and a higher risk of hepatocellular carcinoma than those without coinfection[3].

Recently, interferon (IFN)-based treatment for HCV infection has been gradually replaced by direct-acting antiviral agent (DAA)-based therapy due to the higher HCV sustained virologic response (SVR) rate and greater tolerability of DAA-based therapy. However, concerns have been raised regarding HBV reactivation in patients receiving DAA therapy. HBV reactivation may occur after immunosuppression therapy and chemotherapyand may result in reactivation-related hepatitis, liver failure, need for liver transplantation and even death[4]. Similarly, HBV reactivation can occur in HBV/HCV-coinfected patients undergoing IFN-based or DAA-based treatment[5]. The U.S. Food and Drug Administration (FDA) has reported 29 cases of HBV reactivation, and liver failure occurred in three of these cases after DAA-based treatment[6]. As a result, the FDA introduced a black box warning regarding HBV reactivation risk in HBV/HCV-coinfected patients receiving DAA therapy[7].

A previous meta-analysis reported the proportion of HBV reactivation in HBV/HCV-coinfected individuals, but only two of the included publications involved HBV reactivation with DAA-based therapy. Moreover, the need for preemptive anti-HBV therapy remains controversial[8,9]. Therefore, we conducted a comprehensive meta-analysis to assess the incidence of hepatitis B reactivation in patients receiving DAA-based therapy or IFN-based therapy and the effectiveness of preemptive anti-HBV therapy for preventing HBV reactivation.

**MATERIALS AND METHODS**

***Data search strategy***

This systematic review was based on published literature and included 39 studies. Figure 1 shows the literature search process for the meta-analysis. Relevant publications were extracted from the PubMed, MEDLINE and EMBASE databases from inception to December 30, 2017 using the following key words and subject terms: hepatitis B virus, hepatitis C virus, HBV and HCV dual infection, coinfection and reactivation. The data search was not limited by language or study type. In addition, the reference lists of relevant reviews and online conference abstracts were also screened. When two publications investigated the same population, only the most recent study or the more detailed study was included. Our review adhered to the PRISMA guidelines[10], and the protocol was registered on PROSPERO (registration number: CRD42018085920).

***Study selection***

Studies included in the meta-analysis were required to meet the following criteria: (1) conducted in patients treated with DAA-based therapy or IFN-based therapy; and (2) involved with HBV reactivation or HCV SVR after anti-HCV treatment. The following studies were excluded: (1) studies in patients with human immunodeficiency virus coinfection; and (2) case reports and studies with no extractable data.

The primary outcome was HBV reactivation in accordance with the American Association for the Study of Liver Diseases (AASLD) criteria[11]: (1) chronic HBV infection (HBsAg-positive; increase in HBV DNA > 2 log IU/mL from baseline level or HBV DNA > 100 IU/mL in patients with previously undetectable HBV DNA); and (2) previous HBV infection (HBsAg-negative, HBcAb-positive; HBsAg changed from negative to positive or HBV DNA ≥ 20 IU/mL during treatment). The secondary outcomes included HBV reactivation-related hepatitis, the HCV SVR at the end of anti-HCV treatment and the efficacy of preemptive anti-HBV treatment with nucleos(t)ide analogues (NUCs). A hepatitis flare was defined as a concomitant increase in alanine aminotransferase of at least twice the upper limit of normal.

***Data extraction and quality assessment***

Qualitative studies were selected for the meta-analysis, and both reviews and case reports were excluded. All data were extracted by two independent investigators. The data included the following: study design, study year, country, patient age and sex, total number of patients treated, number of patients with HBV reactivation and reactivation-related hepatitis, number of patients with SVR, HBV DNA level and HBV marker status at baseline, and treatment regimen and duration.

The quality assessment tools (Systematic Evidence Review from the Risk Assessment Work Group) from the National Institutes of Health were used to assess the methodological quality of the cohort studies and randomized controlled trials. Each study was assessed as “good,” “fair,” or “poor” quality using the items included in each tool. Studies of “poor” quality suggested a high risk of bias[12].

***Statistical analysis***

The meta-analysis was conducted in Stata version 14.0 (StataCorp, College Station, TX) using the metan, metaprop, metareg and metabias commands. The incidence rates of HBV reactivation and hepatitis flare were calculated using the random effects model, and the Freeman-Tukey double arcsine transformation was used to stabilize the variance of the raw data[13]. The pooled relative risk (RR) with 95%CIs for HBV reactivation and hepatitis flare was calculated according to the HBV DNA level with an inverse variance approach. The heterogeneity in the pooled studies was estimated with the I2 statistic. Significant heterogeneity was investigated using meta-regression and subgroup analyses for treatment regimen (IFN-based therapy *vs* DAA-based therapy), HBV DNA level (detectable HBV DNA *vs* undetectable HBV DNA), study sample size (*n* < 30 *vs* *n* ≥ 30) and race (Asian *vs* non-Asian). A two-sided *P* value less than 0.05 was regarded as statistically significant. Publication bias was tested using Egger's test and was assessed by funnel plots.

**RESULTS**

***Study characteristics and quality assessment***

The systematic review identified 7092 articles. After the elimination of duplicates, the titles and abstracts were screened, and 39 full articles met the inclusion criteria. These studies were conducted between 1997 and 2017, and included 8 prospective cohort studies[14-21], 27 retrospective cohort studies[22-48], 3randomized controlled trials[49-51] and 1 case-control study[52]. A total of 3468 patients with a median age of 53 years, were enrolled, including 1060 HBsAg-positive patients and 2408 patients with previous HBV infection. Thirty-five of these studies reported the number of HBV reactivations, 35 studies reported the number of hepatitis flares, 36 studies reported the HCV SVR rates, 202 of 203 HBsAg-positive patients and 486 of 507 HBsAg-negative but HBcAb-positive patients achieved HCV SVR with DAA-based therapy. The baseline characteristics are shown in supplementary Table 1.

All articles were assessed as being of fair to good quality. However, studies with a small number of chronic HBV infections may have a potential risk of bias. The small-number effect on the pooled effect size was tested by meta-regression. The quality assessment of the included studies is shown in supplementary Table 2.

***HBV reactivation***

The random effects pooled overall HBV reactivation rate was 15.7% (95%CI: 10.6-21.5) in HBsAg-positive patients receiving anti-HCV treatment with statistical heterogeneity among the studies (*I*2 = 72.6%; *P* < 0.001; Figure 2). Subgroup analysis was performed according to the treatment regimen. The HBV reactivation rate was higher in the DAA-treated group (21.1%, 95%CI: 15.8-26.9) than in the IFN-treated group (11.9%, 95%CI: 6.3-18.6; *P* = 0.02 for subgroup differences). The HBV reactivation risk was further analyzed based on the HBV DNA level. We found that the HBV reactivation rate in patients with undetectable HBV DNA did not differ from that in those with detectable HBV DNA receiving either DAA-based or IFN-based therapy [relative risk (RR) 1.26, 95%CI: 0.84-1.89; *P* = 0.255]. No significant heterogeneity was found among the studies (*I*2 = 32.4%; *P*= 0.123; Figure 3). Egger's test showed a certain publication bias (*P* = 0.03; Figure 4). Univariate meta-regression analysis of the HBV reactivation rate showed that no baseline characteristics influenced the between-subgroup variation (all *P* > 0.05)

In patients with previous HBV infection, the HBV reactivation rate was 0.5% (95%CI: 0-1.3), with significant heterogeneity among the studies (*I*2 = 61.5%; *P* = 0.001; Figure 5). In the subgroup analysis, the incidence of HBV reactivation was not different between the DAA-treated group (0.6%, 95%CI: 0-1.6) and the IFN-treated group (0%, 95%CI: 0-1.1; *P* = 0.241 for subgroup differences). No significant publication bias was found using Egger’s test (*P* = 0.115).

***HBV reactivation-related hepatitis***

The incidence of hepatitis related to HBV reactivation was 0.7% (95%CI: 0-2.6) in HBsAg-positive patients with statistical heterogeneity among the studies (*I*2 = 51.9%; *P*= 0.001; Figure 6). Subgroup analysis revealed that HBsAg-positive patients receiving DAA therapy (3.8%, 95%CI: 0.3-9.5) had a higher rate of HBV reactivation-related hepatitis than those receiving IFN-based therapy (0%, 95%CI: 0-0.9; *P* = 0.007 for subgroup differences). Egger’s test showed a significant publication bias (*P* = 0.015). None of the patients with previous HBV infection experienced hepatitis related to HBV reactivation.

According to baseline HBV DNA level, the rate of hepatitis was lower in patients with undetectable HBV DNA than in patients with detectable HBV DNA (RR = 0.39, 95%CI: 0.17–0.89; *P* = 0.025; Figure 7). Subgroup analysis revealed that the rate of hepatitis was lower in patients with undetectable HBV DNA than in patients with detectable HBV DNA in the DAA-treated group (RR = 0.20, 95%CI: 0.06-0.64; *P* = 0.007). In addition, the incidence of hepatitis was similar in IFN-treated patients with undetectable or detectable HBV DNA (RR = 1.10, 95%CI: 0.26-4.60; *P* = 0.895). No significant heterogeneity was found among the studies (*I*2 = 0%; *P* = 0.633).

***HBV reactivation with and without antiviral prophylaxis***

We identified 6 studies that compared the HBV reactivation rate in HBsAg-positive patients with and without antiviral prophylaxis during DAA-based therapy; these studies included 39 patients who received preemptive anti-HBV treatment at baseline and 104 patients who did not receive preemptive anti-HBV therapy[16,17,22,23,36,41]. None of the 39 patients receiving entecavir or tenofovir developed HBV reactivation, but 21 of the 104 HBsAg-positive patients who did not receive antiviral prophylaxis developed HBV reactivation and five patients developed HBV reactivation-related hepatitis while undergoing DAA therapy. This meta-analysis showed that preemptive anti-HBV therapy with entecavir or tenofovir significantly reduced the risk of HBV reactivation in patients receiving DAA-based treatment (RR = 0.31, 95%CI: 0.1-0.96; *P* = 0.042). No statistical heterogeneity was found among the included studies (*I*2 = 0%; *P* = 0.954; Figure 8).

**DISCUSSION**

Multiple studies have reported HBV reactivation in HCV/HBV coinfected patients treated with DAA, but the reactivation rate is unclear, and the clinical outcome can range from ALT flares to liver failure and even death[16]. We found that the HBV reactivation rate was higher in patients receiving DAA-based therapy than in those receiving IFN-based therapy. A previous study showed an HBV reactivation rate of 12.2% in DAA-treated patients, but only 18 patients treated with DAA were enrolled in the study, and the definition of HBV reactivation was vastly different[5]. The uniform definition of HBV reactivation according to the AASLD criteria was used in our study, and the HBV reactivation rate was higher than that reported by Chen *et al*[5].Furthermore, our review showed that the rate of hepatitis was 3.8% in patients who received DAA-based therapy, whereas the incidence was 0% in patients who received IFN-based therapy. Although the HBV reactivation rate was not different between patients with undetectable or detectable serum HBV DNA at baseline, patients with detectable HBV DNA who received DAAs tended to have a higher proportion of HBV reactivation-related hepatitis. Wang *et al*[15] reported 3 patients who had clinically apparent HBV reactivation, and 1 with hepatic failure. Macera *et al*[16] reported 5 HBsAg-positive patients with hepatitis, 2 of whom developed hepatic failure despite rescue treatment with NUCs. In addition, the FDA reported 3 of 29 patients with HBV reactivation who developed liver failure during treatment with DAAs[6]. HBV reactivation occurred more frequently, and the clinical outcome was more severe, in patients treated with DAAs. This effect may be explained as follows: First, HBV viral replication can be suppressed in patients with HCV infection, and the rapid suppression of HCV viral load by DAAtreatment may create a permissive environment for HBV replication, resulting in HBV reactivation[53]. In addition, IFN exerts an antiviral effect to suppress HBV replication and delay the time to HBV reactivation[54], but DAAs do not have any effect on the innate antiviral immune response.

Our meta-analysis revealed that preemptive anti-HBV therapy with NUCs significantly decreased the HBV reactivation rate. None of the patients receiving entecavir or tenofovir treatment experienced HBV reactivation while undergoing DAA therapy. The AASLD guideline recommends anti-HBV treatment for patients with active HBV infection[9]. However, the European Association for the Study of the Liver guideline recommends that HBsAg-positive patients treated with DAAs should receive concomitant antiviral prophylaxis at least 12 wk after DAA therapy[8]. Our study showes that preemptive anti-HBV treatment with NUCs is effective in preventing HBV reactivation in HBsAg-positive patients, especially in those with detectable HBV DNA who have a high risk of reactivation-related hepatitis.

We found that HBV reactivation was rare in patients with previous HBV infection, that the HBV reactivation rate was not different between patients receiving DAA-based treatment or IFN-based treatment, and that none of these patients experienced HBV reactivation-related hepatitis. Ogawa *et al*[34] reported that the anti-HBs titre may be associated with a risk of HBV reactivation, and that patients with previous HBV infection and negative anti-HBs or very low-titre anti-HBs are at risk of HBV reactivation. According to the results of our study, the HBV DNA level should be monitored during DAA therapy in patients with previous HBV infection, especially those with negative anti-HBs, even though the occurrence of HBV reactivation is rare in these patients.

There are several limitations in this meta-analysis. First, only four randomized controlled trials were included, and most of the studies were cohort studies with a lower data quality for analysis. Second, substantial heterogeneity was observed between the studies and may have caused overestimation or underestimation of the HBV reactivation risk. Third, there was an absence of unified assays for HBV DNA testing in several studies, especially in the IFN-treated group. In addition, we were unable to extract some detailed information that might have had an effect on HBV reactivation such as HBsAg level, anti-HBs titre, and HBV genotype. Further studies should be conducted to obtain relevant information about these parameters. Finally, the effect of the small number studies in our meta-analysis may have influenced the statistical accuracy of the study outcomes.

In conclusion, the present study found that HBV reactivation and hepatitis flare occurred more frequently in HBsAg-positive patients receiving DAA-based anti-HCV treatment than in patients receiving IFN-based therapy. The incidence of HBV reactivation was rare in patients with previous HBV infection. HBV infection had no impact on the efficacy of anti-HCV treatment in patients receiving DAA therapy, but may have reduced the response to IFN therapy. In accordance with the guideline recommendations, our study showed that preemptive anti-HBV therapy with NUCs was effective in preventing HBV reactivation in HBsAg-positive patients, especially those with detectable serum HBV DNA. In patients with previous HBV infection receiving DAA treatment for HCV, especially those with negative anti-HBs, the ALT level and HBV DNA level should be monitored. Further studies are required to assess the cost effectiveness of preemptive anti-HBV therapy in HBsAg-positive patients receiving DAA-based therapy.

**ARTICLE HIGHLIGHTS**

***Research background***

Hepatitis B virus/hepatitis C virus (HBV/HCV) dual infection is common in regions with high HBV prevalence, as HBV and HCV share a similar mode of transmission. HBV/HCV-coinfected patients tend to have more severe liver fibrosis and a higher risk of hepatocellular carcinoma than those without coinfection. HBV reactivation may occur after patients receive direct-acting antiviral agent (DAA)-based therapy or interferon (IFN)-based therapy for hepatitis C. Several studies have reported HBV reactivation but a meta-analysis to determine the proportion of HBV reactivation is still lacking.

***Research motivation***

Although previous studies reported HBV reactivation in patients undergoing DAA-based therapy or IFN-based therapy, the results indicate contradictory HBV reactivation rates. Moreover, the need for preemptive anti-HBV therapy remains controversial.

***Research objectives***

The main objectives of the systematic review and meta-analysis were to evaluate the incidence of HBV reactivation in patients receiving DAA-based therapy or IFN-based therapy for hepatitis C and the effectiveness of preemptive anti-HBV therapy for preventing HBV reactivation.

***Research methods***

Relevant publications were searched in the PubMed, MEDLINE and EMBASE databases with the indicated key words and subject terms. The data were extracted, and statistical analysis was conducted in Stata to assess the incidence of HBV reactivation and reactivation-related hepatitis. Significant heterogeneity was investigated using meta-regression and subgroup analyses for treatment regimen, HBV DNA level, study sample size and race. Publication bias was tested using Egger's test and was assessed by funnel plots.

***Research results***

The systematic review identified 7092 articles and enrolled 39 full articles that met the inclusion criteria. The pooled random effects overall HBV reactivation rate was 15.7% (95%CI: 10.6-21.5) in hepatitis B surface antigen (HBsAg)-positive patients. The HBV reactivation rate was higher in the DAA-treated group (21.1%, 95%CI: 15.8-26.9) than in the IFN-treated group (11.9%, 95%CI: 6.3-18.6). The incidence of hepatitis related to HBV reactivation was 0.7% (95%CI: 0-2.6) in HBsAg-positive patients and patients receiving DAA therapy (3.8%, 95%CI: 0.3-9.5) had a higher rate of HBV reactivation-related hepatitis than those receiving IFN-based therapy (0%, 95%CI: 0-0.9). Preemptive anti-HBV therapy with entecavir or tenofovir significantly reduced the risk of HBV reactivation in patients receiving DAA-based treatment (RR = 0.31, 95%CI: 0.1-0.96).

***Research conclusions***

Our study found that HBV reactivation and hepatitis flare occurred more frequently in HBsAg-positive patients receiving DAA-based anti-HCV treatment than in patients receiving IFN-based therapy. HBV reactivation was rare in patients with previous HBV infection. Preemptive anti-HBV therapy with NUCs was effective in HBsAg-positive patients to prevent HBV reactivation, especially in those with detectable serum HBV DNA.

***Research perspectives***

Our study found the high risk of HBV reactivation in patients receiving DAA-based therapy for hepatitis C. Preemptive anti-HBV treatment proved to be effective in preventing HBV reactivation during DAA therapy. However, more high quality randomized controlled trials are needed to assess the risk of HBV reactivation in patients with HBV/HCV coinfection. Further investigation is required to assess the cost effectiveness of treating HBV/HCV-coinfected patients with NUCs prior to initiating DAA therapy.

**REFERENCES**

1 **Stanaway JD**, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad LJ, Assadi R, Bhala N, Cowie B, Forouzanfour MH, Groeger J, Hanafiah KM, Jacobsen KH, James SL, MacLachlan J, Malekzadeh R, Martin NK, Mokdad AA, Mokdad AH, Murray CJL, Plass D, Rana S, Rein DB, Richardus JH, Sanabria J, Saylan M, Shahraz S, So S, Vlassov VV, Weiderpass E, Wiersma ST, Younis M, Yu C, El Sayed Zaki M, Cooke GS. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. *Lancet* 2016; **388**: 1081-1088 [PMID: 27394647 DOI: 10.1016/s0140-6736(16)30579-7]

2 **Liu CJ**, Chen PJ, Chen DS. Dual chronic hepatitis B virus and hepatitis C virus infection. *Hepatol Int* 2009; **3**: 517-525 [PMID: 19669238 DOI: 10.1007/s12072-009-9147-9]

3 **Lee LP**, Dai CY, Chuang WL, Chang WY, Hou NJ, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chen TJ, Yu ML. Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients. *J Gastroenterol Hepatol* 2007; **22**: 515-517 [PMID: 17376043 DOI: 10.1111/j.1440-1746.2006.04547.x]

4 **Di Bisceglie AM**, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? *Hepatology* 2015; **61**: 703-711 [PMID: 25412906 DOI: 10.1002/hep.27609]

5 **Chen G**, Wang C, Chen J, Ji D, Wang Y, Wu V, Karlberg J, Lau G. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. *Hepatology* 2017; **66**: 13-26 [PMID: 28195337 DOI: 10.1002/hep.29109]

6 **Bersoff-Matcha SJ**, Cao K, Jason M, Ajao A, Jones SC, Meyer T, Brinker A. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. *Ann Intern Med* 2017; **166**: 792-798 [PMID: 28437794 DOI: 10.7326/M17-0377]

7 **Pockros PJ**. Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection. *Gastroenterol Hepatol (N Y)* 2017; **13**: 536-540 [PMID: 29038644]

8 **European Association for the Study of the Liver**. EASL Recommendations on Treatment of Hepatitis C 2016. *J Hepatol* 2017; **66**: 153-194 [PMID: 27667367 DOI: 10.1016/j.jhep.2016.09.001]

9 **American Association for the Study of Liver Disease, Infectious Diseases Society of America.** Recommendations for testing, managing, and treating hepatitis C, 2016. Available from: URL: http://hcvguidelines.org/sites/default/files/HCV-Guidance\_October\_2016\_a.pdf

10 **Liberati A**, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Ann Intern Med* 2009; **151**: W65-W94 [PMID: 19622512]

11 **Hwang JP**, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. *Nat Rev Gastroenterol Hepatol* 2014; **11**: 209-219 [PMID: 24247262 DOI: 10.1038/nrgastro]

12 **Brewer JD**, Elston DM, Vidimos AT, Rizza SA, Miller SJ. Managing sharps injuries and other occupational exposures to HIV, HBV, and HCV in the dermatology office. *J Am Acad Dermatol* 2017; **77**: 946-951.e6 [PMID: 28865865 DOI: 10.1016/j.jaad.2017.06.040]

13 **Nyaga VN**, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. *Arch Public Health* 2014; **72**: 39 [PMID: 25810908 DOI: 10.1186/2049-3258-72-39]

14 **Liu J**. Hepatitis B reactivation in chronic hepatitis C patients treated with interferon or pan-oral direct-acting antivirals. *Hepatology* 2018; **67**: 453-454 [PMID: 29080221 DOI: 10.1002/hep.29620]

15 **Wang C**, Ji D, Chen J, Shao Q, Li B, Liu J, Wu V, Wong A, Wang Y, Zhang X, Lu L, Wong C, Tsang S, Zhang Z, Sun J, Hou J, Chen G, Lau G. Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents. *Clin Gastroenterol Hepatol* 2017; **15**: 132-136 [PMID: 27392759 DOI: 10.1016/j.cgh.2016.06.023]

16 **Macera M**, Stanzione M, Messina V, D'Adamo G, Sangiovanni V, Mioglioresi L, Fontanella L, De Pascalis S, Stornaiuolo G, Galeota Lanza A, Ascione T, Sagnelli E, Gentile I, Piai G, Gaeta GB, Coppola N. Interferon-Free Regimens in Hepatitis B Surface Antigen/Anti-Hepatitis C Virus Positive Patients: The Need to Control Hepatitis B Virus Replication to Avoid Hepatitis B Virus Reactivation. *Clin Gastroenterol Hepatol* 2017; **15**: 1800-1802 [PMID: 28552801 DOI: 10.1016/j.cgh.2017.05.032]

17 **Londoño MC**, Lens S, Mariño Z, Bonacci M, Ariza X, Broquetas T, Pla A, Bartres C, Adriani MV, Rodríguez-Tajes S, Costa J, Carrión JA, Pérez-Del-Pulgar S, Forns X. Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen. *Aliment Pharmacol Ther* 2017; **45**: 1156-1161 [PMID: 28206681 DOI: 10.1111/apt.13985]

18 **Doi A**, Sakamori R, Tahata Y, Urabe A, Morishita N, Yamada R, Furuta K, Kodama T, Hikita H, Yakushijin T, Ohkawa K, Kaneko A, Imai Y, Tatsumi T, Takehara T. Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort. *Hepatol Res* 2017; **47**: 1438-1444 [PMID: 28585404 DOI: 10.1111/hepr.12919]

19 **Gane EJ**, Hyland RH, An D, Svarovskaia ES, Brainard D, McHutchison JG. Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV. *Antivir Ther* 2016; **21**: 605-609 [PMID: 27367295 DOI: 10.3851/imp3066]

20 **Saitta C**, Pontisso P, Brunetto MR, Fargion S, Gaeta GB, Niro GA, Picciotto A, Smedile A, Squadrito G, Raimondo G. Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy. *Antivir Ther* 2006; **11**: 931-934 [PMID: 17302256]

21 **Villa E**, Grottola A, Buttafoco P, Colantoni A, Bagni A, Ferretti I, Cremonini C, Bertani H, Manenti F. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. *Am J Gastroenterol* 2001; **96**: 2973-2977 [PMID: 11693335 DOI: 10.1016/S0002-9270(01)03232-4]

22 **Belperio PS**, Shahoumian TA, Mole LA, Backus LI. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. *Hepatology* 2017; **66**: 27-36 [PMID: 28240789 DOI: 10.1002/hep.29135]

23 **Calvaruso V**, Ferraro D, Licata A, Bavetta MG, Petta S, Bronte F, Colomba G, Craxì A, Di Marco V. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals. *J Viral Hepat* 2018; **25**: 72-79 [PMID: 28703895 DOI: 10.1111/jvh.12754]

24 **Aygen B**, Günalo, Yildiz O, Çelen MK, Akhan S, Barut S, Ayaz C. Hepatitis B Virus and Hepatitis C Virus Co-infection: An Evaluation of Eighty-Two Patients. *J Viral Hepat* 2017; **23**: 14-19 [DOI: 10.4274/vhd.75768]

25 **Guptan RC**, Thakur V, Raina V, Sarin SK. Alpha-interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses. *J Gastroenterol Hepatol* 1999; **14**: 893-898 [PMID: 10535471 DOI: 10.1046/j.1440-1746.1999.01952.x]

26 **Hasegawa I**, Orito E, Tanaka Y, Hirashima N, Sakakibara K, Sakurai M, Suzuki S, Sugauchi F, Ohno T, Ueda R, Mizokami M. Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C. *Liver Int* 2005; **25**: 247-253 [PMID: 15780046 DOI: 10.1111/j.1478-3231.2005.1096.x]

27 **Hung CH**, Lu SN, Wang JH, Hu TH, Chen CH, Huang CM, Lee CM. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients. *Antivir Ther* 2011; **16**: 959-968 [PMID: 22024511 DOI: 10.3851/imp1842]

28 **Kawagishi N**, Suda G, Onozawa M, Kimura M, Maehara O, Ohara M, Izumi T, Umemura M, Ito J, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C. *J Viral Hepat* 2017; **24**: 1098-1106 [PMID: 28632923 DOI: 10.1111/jvh.12737]

29 **Kim YJ**, Lee JW, Kim YS, Jeong SH, Kim YS, Yim HJ, Kim BH, Lee CK, Park CK, Park SH. Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus. *Korean J Hepatol* 2011; **17**: 199-205 [PMID: 22102386 DOI: 10.3350/kjhep.2011.17.3.199]

30 **Liu CJ**, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, Liao LY, Chen CL, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Liu CH, Su WW, Lin CL, Jeng YM, Chen PJ, Chen DS. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. *Gastroenterology* 2009; **136**: 496-504.e3 [PMID: 19084016 DOI: 10.1053/j.gastro.2008.10.049]

31 **Loggi E**, Gitto S, Galli S, Minichiello M, Conti F, Grandini E, Scuteri A, Vitale G, Di Donato R, Cursaro C, Furlini G, Andreone P. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice. *J Clin Virol* 2017; **93**: 66-70 [PMID: 28654775 DOI: 10.1016/j.jcv.2017.05.021]

32 **Mücke VT**, Mücke MM, Peiffer KH, Weiler N, Welzel TM, Sarrazin C, Zeuzem S, Berger A, Vermehren J. No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort. *Aliment Pharmacol Ther* 2017; **46**: 432-439 [PMID: 28627791 DOI: 10.1111/apt.14177]

33 **Myers RP**, Thibault V, Poynard T. The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C. *J Viral Hepat* 2003; **10**: 103-110 [PMID: 12614466 DOI: 10.1046/j.1365-2893.2003.00407.x]

34 **Ogawa E**, Furusyo N, Murata M, Toyoda K, Hayashi T, Ura K. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV. *Liver Int* 2018; **38**: 76-83 [PMID: 28618152 DOI: 10.1111/liv.13496]

35 **Potthoff A**, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, Spengler U, Gruengreiff K, Kaeser T, Schuchmann M, Bergk A, Forestier N, Deterding K, Manns MP, Trautwein C; Hep-Net B/C Co-infection Study Group. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. *J Hepatol* 2008; **49**: 688-694 [PMID: 18490077 DOI: 10.1016/j.jhep.2008.03.028]

36 **Preda C,** Popescu C, Constantinescu I, Manuc M, Tugui L, Voiosu R, Ceausu E, Diculescu M, Oproiu A. Outcome of patients with compensated liver cirrhosis with hepatitis B virus + hepatitis C virus coinfection treated with paritaprevir/ombitasvir/ritonavir, dasabuvir with ribavirin: a national cohort study. *J Hepatol* 2017; **66**: S295-S296 [DOI: 10.1016/s0168-8278(17)30907-8]

37 **Senturk H**, Tahan V, Canbakan B, Uraz S, Ulger Y, Ozaras R, Tabak F, Mert A, Ozbay G. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers. *Neth J Med* 2008; **66**: 191-195 [PMID: 18490796]

38 **Serpil E,** Ozkurt Z, Ozbek A, Parlak M. Poor Response to Treatment with Peg-IFN Containing Regimens in Patients Coinfected with Hepatitis B and Hepatitis C Virus. *Hepat Mon* 2009; **9**: 224–228

39 **Sulkowski MS**, Chuang WL, Kao JH, Yang JC, Gao B, Brainard DM, Han KH, Gane E. No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection. *Clin Infect Dis* 2016; **63**: 1202-1204 [PMID: 27486112 DOI: 10.1093/cid/ciw507]

40 **Szymanek-Pasternak A**, Simon KA, Serafińska S, Janocha-Litwin J, Pazgan-Simon M, Madej G. The influence of anti-HBc status on the sustained virological response rate in HCV-infected patients treated with pegylated interferon alfa 2 and ribavirin. *Clin Exp Hepatol* 2016; **2**: 155-160 [PMID: 28856281 DOI: 10.5114/ceh.2016.63873]

41 **Tamori A**, Abiru S, Enomoto H, Kioka K, Korenaga M, Tani J, Enomoto M, Sugiyama M, Masaki T, Kawada N, Yatsuhashi H, Nishiguchi S, Mizokami M. Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy. *J Viral Hepat* 2018; **25**: 608-611 [PMID: 29194858 DOI: 10.1111/jvh.12840]

42 **Tang L,** Tolaymat M, Stonesifer E, Kottilil S, Wilson E. Absence of hepatitis B reactivation among veterans with serological evidence of previous hepatitis B infection receiving anti-hepatitis C direct acting antivirals. *J Hepatol* 2017; **66**: S251-S252 [DOI: 10.1016/s0168-8278(17)30811-5]

43 **Viganò M**, Aghemo A, Iavarone M, Rumi MG, Agnelli F, Lampertico P, Donato MF, Colombo M. The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin. *Antivir Ther* 2009; **14**: 789-796 [PMID: 19812441 DOI: 10.3851/imp1284]

44 **Weltman MD**, Brotodihardjo A, Crewe EB, Farrell GC, Bilous M, Grierson JM, Liddle C. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. *J Viral Hepat* 1995; **2**: 39-45 [PMID: 7493293]

45 **Yalcin K,** Degertekin H. A 12 Month Course of Combination Therapy with Interferon and Ribavirin in Chronic Hepatitis due to Coinfection with Hepatitis B and C Viruses. *Clin Drug Invest* 2002; **22**: 797-798[DOI: 10.2165/00044011-200222110-00009]

46 **Yeh ML**, Huang CF, Hsieh MH, Ko YM, Chen KY, Liu TW, Lin YH, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang CI, Huang JF, Kuo PL, Dai CY, Yu ML, Chuang WL. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. *J Gastroenterol Hepatol* 2017; **32**: 1754-1762 [PMID: 28230928 DOI: 10.1111/jgh.13771]

47 **Yu JW**, Sun LJ, Zhao YH, Kang P, Gao J, Li SC. Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus. *Liver Int* 2009; **29**: 1485-1493 [PMID: 19602134 DOI: 10.1111/j.1478-3231.2009.02080.x]

48 **Zignego AL**, Fontana R, Puliti S, Barbagli S, Monti M, Careccia G, Giannelli F, Giannini C, Buzzelli G, Brunetto MR, Bonino F, Gentilini P. Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. *Arch Virol* 1997; **142**: 535-544 [PMID: 9349299]

49 **Liu CJ**, Chuang WL, Sheen IS, Wang HY, Chen CY, Tseng KC, Chang TT, Massetto B, Yang JC, Yun C, Knox SJ, Osinusi A, Camus G, Jiang D, Brainard DM, McHutchison JG, Hu TH, Hsu YC, Lo GH, Chu CJ, Chen JJ, Peng CY, Chien RN, Chen PJ. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. *Gastroenterology* 2018; **154**: 989-997 [PMID: 29174546 DOI: 10.1053/j.gastro.2017.11.011]

50 **Yeh ML**, Hsieh MY, Huang CI, Huang CF, Hsieh MH, Liang PC, Lin YH, Hou NJ, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML. Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study. *Medicine (Baltimore)* 2015; **94**: e1837 [PMID: 26496327 DOI: 10.1097/md.0000000000001837]

51 **Liaw YF**, Chien RN, Lin SM, Yeh CT, Tsai SL, Sheen IS, Chu CM. Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. *J Interferon Cytokine Res* 1997; **17**: 449-452 [PMID: 9282824 DOI: 10.1089/jir.1997.17.449]

52 **Chuang WL**, Dai CY, Chang WY, Lee LP, Lin ZY, Chen SC, Hsieh MY, Wang LY, Yu ML. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. *Antivir Ther* 2005; **10**: 125-133 [PMID: 15751770]

53 **Eyre NS**, Phillips RJ, Bowden S, Yip E, Dewar B, Locarnini SA, Beard MR. Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. *J Hepatol* 2009; **51**: 446-457 [PMID: 19596477 DOI: 10.1016/j.jhep.2009.04.025]

54 **Lau GK**, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. *N Engl J Med* 2005; **352**: 2682-2695 [PMID: 15987917 DOI: 10.1056/NEJMoa043470]

**P-Reviewer:** Sharafi H, Shimizu Y **S-Editor:** Wang JL

**L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

Records identified through database searching  
(*n* = 7092 )

Additional records identified through other sources  
(*n* = 11)

Records after duplicates removed  
(*n* = 3612)

Records screened  
(*n* = 3612 )

Records excluded  
(*n* = 3499 )

Full-text articles assessed for eligibility  
(*n* = 113 )

Full-text articles excluded  
(*n* = 74)

13 case reports

19 repeated studies

26 did not involve anti-HCV treatment

14 full text was not available

2 coinfected with HIV

Studies included in qualitative synthesis  
(*n* = 39 )

Studies included in quantitative synthesis (meta-analysis)  
(*n* = 39 )

**Figure 1 Literature search process for the systematic review and meta-analysis.** HCV: Hepatitis C virus; HIV: Human immunodeficiency virus.




**Figure 2 Hepatitis B virus reactivation in hepatitis C virus patients with chronic hepatitis B virus infection.** Pooled estimates of hepatitis B virus reactivation in hepatitis C virus patients with chronic hepatitis B surface antigen-positive hepatitis B virus infection.



**Figure 3 Hepatitis B virus reactivation according to baseline hepatitis B virus DNA level in hepatitis C virus patients with chronic hepatitis B virus infection**. Relative risk of hepatitis B virus (HBV) reactivation according to baseline HBV DNA level in hepatitis C virus patients with chronic (hepatitis B surface antigen-positive) HBV infection.

**Figure 4 Funnel plot of 26 studies estimating the hepatitis B virus reactivation rates in hepatitis C virus patients with chronic hepatitis B virus infection**. The vertical line corresponds to the summary hepatitis B virus reactivation rates as estimated from the random effect model. The publication bias is presented; *P* = 0.03, as tested by Egger’s test.




**Figure 5 Hepatitis B virus reactivation in hepatitis C virus patients with previous hepatitis B virus infection.** Pooled estimates of hepatitis B virus (HBV) reactivation in hepatitis C virus patients with previous hepatitis B surface antigen-negative but HBcAb-positive HBV infection.

****

**Figure 6 Hepatitis B virus reactivation-related hepatitis in hepatitis C virus patients with chronic hepatitis B virus infection.** Overall risk of hepatitis B virus (HBV) reactivation-related hepatitis in hepatitis C virus patients with chronic hepatitis B surface antigen-positive HBV infection.

****

**Figure 7 Hepatitis B virus reactivation-related hepatitis according to baseline hepatitis B virus DNA level.** Relative risk of hepatitis B virus (HBV) reactivation-related hepatitis according to baseline HBV DNA level in hepatitis C virus patients with chronic hepatitis B surface antigen-positive HBV infection.

****

**Figure 8 Hepatitis B virus reactivation in hepatitis B surface antigen-positive patients with and without antiviral prophylaxis.** Relative risk of hepatitis B virus reactivation in hepatitis B surface antigen-positive patients with antiviral prophylaxis and without prophylaxis.